Furthermore, Minghua Yang et al. [37] demonstrated that cholesterol-lowering probiotics (e.g., Lactobacillus and Bifidobacterium) can modulate the FXR–FGF15 axis by altering gut microbiota composition and bile acid metabolism, thereby alleviating non-alcoholic fatty liver disease and dyslipidemia. The gene discussed is NR1H4; the disease is metabolic syndrome.